Company intelligence / Profile preview

BBS-Bioactive Bone Substitutes

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

The company’s lead product ARTEBONE® Paste has completed preclinical safety and performance testing as a medical device. It was in the final stages of the CE marking process for commercialization in the EU market by late 2024. However, as of February 17, 2025, the company was declared bankrupt by Oulu District Court.

Therapeutic areas: OtherRheumatology
Modalities: DeviceBiologic (bioactive bone-graft substitute implant)Protein (contains natural spectrum of bone growth factors)Peptides (as part of the natural bone matrix proteins)
Industry: Implantable Medical Devices

Drug pipeline

3 assets

ARTEBONE

Pre-clinical

Indications: Bone void filling

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on BBS-Bioactive Bone Substitutes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBS-Bioactive Bone Substitutes.

Explore the full profile